This course has expired. View available courses.
Oncology
ESMO in Focus: Prostate Cancer
Hear from this leading panel of Australian medical oncologists who review and analyse three practice-shaping European Society of Medical Oncology (ESMO) prostate cancer presentations, the PEACE-1 study, the ARCHES study and the STAMPEDE trial (M0 cohort)
In this video, our experts debate the role of earlier integration of intensified systemic therapy in clinical trials and how this may translate into changes of clinical practice, to achieve better outcomes for men with prostate cancer.
The PEACE-1 trial tested the combination of standard of care +/- abiraterone in M1 hormone-sensitive prostate cancer on conventional imaging. Outcomes in patients treated with ADT + Docetaxel as part of standard of care are discussed, including for which group of patients triple therapy could become a new standard of care.
The ARCHES study examines the effect of ADT +/- enzalutamide in M1 hormone-sensitive prostate cancer. The faculty discusses the reported overall survival data and subgroups supporting the use of enzalutamide.
Our experts’ discussion on the STAMPEDE trial (M0) focuses on high-risk nonmetastatic hormone-sensitive prostate cancer.
This program is proudly supported by Astellas.
DURATION
1 hr
PROFESSION
Specialist
# OF CREDITS
0
ACCREDITATION
Unaccredited
EXPIRY DATE
2022-12-01
Hear from this leading panel of Australian medical oncologists who review and analyse three practice-shaping European Society of Medical Oncology (ESMO) prostate cancer presentations, the PEACE-1 study, the ARCHES study and the STAMPEDE trial (M0 cohort)
In this video, our experts debate the role of earlier integration of intensified systemic therapy in clinical trials and how this may translate into changes of clinical practice, to achieve better outcomes for men with prostate cancer.
The PEACE-1 trial tested the combination of standard of care +/- abiraterone in M1 hormone-sensitive prostate cancer on conventional imaging. Outcomes in patients treated with ADT + Docetaxel as part of standard of care are discussed, including for which group of patients triple therapy could become a new standard of care.
The ARCHES study examines the effect of ADT +/- enzalutamide in M1 hormone-sensitive prostate cancer. The faculty discusses the reported overall survival data and subgroups supporting the use of enzalutamide.
Our experts’ discussion on the STAMPEDE trial (M0) focuses on high-risk nonmetastatic hormone-sensitive prostate cancer.
This program is proudly supported by Astellas.
Faculty
A/Prof Arun Azad – Program Chair, MBBS, PhD, FRACP
Dr Louise Kostos, MBBS, FRACP
Dr Megan Crumbaker, MBBS, PhD, FRACP
# of credits: 0
Duration: 1 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
